The pill times 2: What every woman with multiple sclerosis should know

Neurology

Volumn 82, Issue 8, 2014, Pages 654-655

  Langer Gould, Annette M ^a,b  

^a KAISER PERMANENTE   (United States)

^b LOS ANGELES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; TERIFLUNOMIDE;

ALBUMIN BLOOD LEVEL; BODY SURFACE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; EDITORIAL; FETUS DISEASE; FETUS OUTCOME; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HUMAN; MOLECULAR SIZE; MULTIPLE SCLEROSIS; ORGANOGENESIS; OSSIFICATION; OUTCOME ASSESSMENT; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; TERATOGENESIS; TERATOGENICITY; UNPLANNED PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PREGNANCY; PREGNANCY COMPLICATIONS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84895790850     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000155     Document Type: Editorial

References (9)

1. Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014;82:674-680.
2. World Health Organization. Congenital anomalies: fact sheet No370. Available at: http://www.who.int/mediacentre/ factsheets/fs370/en/index.html. Accessed October 17, 2013.
3. Thomas SHL, Yates LM. Prescribing without evidence: pregnancy. Br J Clin Pharmacol 2012;74:691-697.
4. Food and Drug Administration. Fingolimod package insert. Revised May 2012.
5. Food and Drug Administration. Teriflunomide package insert. Revised September 2012.
6. Food and Drug Administration. Dimethyl fumarate pharmacology review submitted on 2/27/2012. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2013/ 204063Orig1s000PharmR.pdf. Accessed October 17, 2013.
7. Malek A, Sager R, Zakher A, Schneider H. Transport of immunoglobulin G and its subclasses across the in vitroperfused human placenta. Am J Obstetrics Gynecol 1995; 173:760-767.
8. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011;17: 958-963.
9. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012;79: 1130-1135.